The ELISpot and FluoroSpot Assay market is expected to grow at a CAGR of 16.1% to reach USD 710.03 Million in 2030.
.jpg "The Global Elispot And Fluorospot Assay Market 2020-2030 (USD Million)")
The global ELISpot and FluoroSpot assay market was valued at USD 148.6 million in 2019. Growing focus on DNA vaccine development, increasing burden of chronic diseases coupled rapid technological advancements are key factors driving the global ELISpot and FluoroSpot assay market.
ELISpot and Fluorospot assays are used for analyzing the immune system at a single-cell level. The cells are cultured and stimulated on plates coated with antibody production that capture specific target molecules released by the activated cells. FluoroSpot assay employs sandwich ELISA technology, with fluorescence detection instead of chromogenic detection. FluoroSpot assay are used in the analysis of cytokines and other soluble molecules produced from secreting T-cells and enables identification of secreted products at a single cell therapy level. The techniques are widely used in the R&D of various infectious diseases and in cancer research. Increase in infectious diseases, growing focus on vaccine development along with rapid technological advancements are major factors propelling the growth of the market.
The global ELISpot and FluoroSpot assay market has been segmented into product, application, end-users, and region. Based on product, the global ELISpot and FluoroSpot assay market is categorized into assay kits, analyzers, and ancillary products. In 2019, assay kits segment held dominant share of the global market. By application, diagnostic application segment grabbed majority of the share of the global ELISpot and FluoroSpot assay market in 2019. Geographically, North America dominated the global ELISpot and FluoroSpot assay market in 2019, however, Asia Pacific is expected to be the fastest growing region by 2028.
Key players operating in the global ELISpot and FluoroSpot assay market include Oxford Immunotec, Cellular Technology Limited, BD, AID GmbH, Mabtech, Bio-Techne, Lophius Biosciences, Abcam, Biotech Investissement Group, and U-CyTech biosciences among others.
ELISpot and FluoroSpot Assay Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2030 |
| Study Period | 2018-2030 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2030 | USD 710.03 Million |
| Growth Rate | CAGR of 16.1% during 2020-2030 |
| Segment Covered | By Product, Regions |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others. |
Key Segment Of The ELISpot and FluoroSpot Assay Market
By Product (USD Million)
• Assay Kit
• Ancillary Products
Application, (USD Million)
• Transplant
• Vaccines
End-User, (USD Million)
• Hospitals And Clinics
• Ambulatory Surgical Centres
• Diagnostic Centres
• Research Centers
Regional Overview, (USD Million)
North America
• US
• Canada
Europe
• Germany
• France
• UK
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Rest of Asia Pacific
South America
• Mexico
• Brazil
• Rest of South America
Middle East and South Africa
Frequently Asked Questions (FAQ) :
the elispot and fluorospot assay market is growing at a CAGR of 16.1% during the forecast period.
The market value of elispot and fluorospot assay market in 2030 was USD 710.03 Million
North America dominated the market for elispot and fluorospot assay market and accounted for the largest revenue share
ELISA and Immunoblot are some of the assays designed to measure antibody reactivity and specificity. However, ELISpot and FluoroSpot are assays that focus directly on the antibody-secreting cells (ASC). FluoroSpot has emerged as an attractive alternative to ELISpot. Benefits offered by FluoroSpot assay such as its ability to identify secreting cells using detection reagents labeled with fluorophores instead of enzymes will drive its adoption rate. Moreover, the fluorophore-based detection enables analysis of multiple analytes in one and the same well. Thus, FluoroSpot has been used to analyze dual cytokine secretion by polyfunctional T cells as well as the cytokine profile of monocyte subsets. Moreover, key industry players such as Oxford Immunotec and Cellular Technology Limited focus on development of advanced ELISpot and FluoroSpot assay kits and analyzers which will offer immense growth opportunities in the future.
The global ELISpot and FluoroSpot assay market has been segmented based on product, application, end-users, and region. Based on product, the global ELISpot and FluoroSpot assay market is categorized into assay kits, analyzers, and ancillary products. Assay kits segment grabbed majority of the market share in 2019 owing to increase in burden of chronic ailments across the globe.
Application-wise, the global ELISpot and FluoroSpot assay is segmented into diagnostic applications and research applications. In 2019, diagnostic application segment grabbed majority of the share of the global market owing to rise in incidence of infectious diseases worldwide along with rapid adoption of ELISpot kits for disease diagnosis.
On the basis of end-users, the global ELISpot and FluoroSpot assay market is segmented into hospitals & clinical laboratories, research institutes, and biotechnology companies. Hospitals held majority of the market share in 2019. Hospitals are well-equipped with technologically advanced equipment and devices to improve patient care and have availability of specialists. Moreover, increasing adoption of point-of-care testing in these facilities for rapid diagnosis and treatment will boost segment growth over the forecast period.
The global ELISpot and FluoroSpot assay market is cumulative to North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global ELISpot and FluoroSpot assay market in 2019, however Asia Pacific is expected to grow at a highest pace through 2028.
Rapid adoption of ELISpot and FluoroSpot assay kits for disease diagnosis, increase in incidences of infectious diseases, growing focus on vaccine development for antimicrobial resistance in the U.S. and Canada are factors anticipated to drive the ELISpot and FluoroSpot assay market in the region. Furthermore, presence of well-established industry players offering ELISpot and FluoroSpot assay kits and analyzers are other major factors likely to boost the growth of the market in North America.
However, Asia Pacific is expected to grow at a rapid pace over the next few years. There is a strong growth potential in the emerging economies such as India, and China. Increased cases of chronic diseases, large patient pool in low- and middle-income countries is expected to create huge growth opportunities for market players to tap these regions which will eventually foster the demand for ELISpot and FluoroSpot assay in the future.